Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Compass Pathways PLC

CMPS ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$14.54

▲ +1.32%

Market Cap $2.01B · Vol 599.37K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.01B

Mid Cap

Div Yield

N/A

EPS Growth

+28.25%

YoY

RSI (14)

53.01

Momentum

Beta

2.54

vs Market

52W High

$15.86

8.32% below

52W Low

$4.83

201.04% above

Volume

599.37K

Avg 622.57K

P/B

N/A

Price-to-book

ROE

-277.47%

Return on equity

Free Float

92.38%

Public shares

Shariah Compliance8 STANDARDS

✗ Compass Pathways PLC (CMPS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CMPS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+9.57%

+8.10%

+20.36%

+127.54%

YTD

+110.72%

+179.62%

+54.52%

-54.39%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-287,862,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-277.47%
ROA · ROIC	-136.95% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+28.25%
Outstanding Shares	138.48M

Technical Indicators

50-Day SMA	$13.15
200-Day SMA	$9.39
RSI (14)	53.01
Beta	2.54
52-Week High	$15.86
52-Week Low	$4.83

Volume Today	599.37K
Avg Daily Volume (30D)	622.57K
Relative Volume	0.96x
Volatility (10D)	59.11
Volatility (30D)	68.62
Free Float	92.38%

Analyst Consensus

BUY

Current Price $14.54

Mean Target $21.97

52W Low$4.83 52W High$15.86

Current

Target

$4.83 $15.86

Current Analyst target

+51.12% upside potential · 16 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00X0VY3F8

ISINUS20451W1018

CountryUK

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.56% ONC BeOne Medicines AG +2.11% 068270.KS Celltrion, Inc. +0.34% ABVX Abivax SA -4.27% ABVX.PA Abivax SA -1.63%

Company Profile

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.